regenon retard 60 mg buy regenon 60mg
$80.00 $60.00
PZN: 4111794
Pack size: 60 pieces
Delivery form: anesthetic
Presentation: Sustained-Release Capsules
Providers: Hormosan Pharma GmbH
Description
regenon retard 60 mg
regenon retard 60 mg prolonged-release capsule Auxiliary in the treatment of exogenous obesity, associated with a hypocaloric and exercise diet.
product features
General Info

composition: Amfepramon hydrochloride 60 mg
Dosage Form: capsules
excipients: gelatin
anesthetic: No
medical device: No
providers: Hormosan Pharma GmbH
ingredient
Active ingredient:
- Amfepramon hydrochloride (60 mg per 1 capsule)= Amfepramon (50.95 mg per 1 capsule)
Other ingredients:
- corn starch
- sucrose
- shellac
- ethylcellulose
- tartaric acid
Other components
- Povidon K30
- talc
- Silicon dioxide, highly disperse
- gelatin
- Indigo carmine
- erythrosine
- Titanium dioxide
- Iron (III) oxide hydrate, black
application areas
– Obesity with a body mass index (BMI) of at least 30 kg / m 2 The body mass index (BMI) = body weight in kilograms divided by body size in meters squared.
Dosage of regenon retard 60 mg capsules
- Young people from 12 years and adults
- Single / total dose: 1 capsule / once a day
- Time: 2 hours before lunch
storage
side effects
- Like all medicines, Regenon can have side effects, although not everybody gets them.
- The following frequency information is used to evaluate side effects
- Very common: affects more than 1 user in 10
- Common: affects 1 to 10 users in 100
- Uncommon: affects 1 to 10 users in 1,000
- Rare: affects 1 to 10 users in 10,000
- Very rare: less than 1 in 10,000 people
- Not known: frequency cannot be estimated from the available data
Side effects of regenon retard 60 mg capsules
- – Nausea
- – dry mouth
- – constipation
- – headache
- – dizziness
- – drowsiness
- – sleep disorders
- – restlessness and tension
- – irritability and nervousness
- – depression
- – delirium (confusion)
- – seizures
- – high blood pressure
- – pulse acceleration
- – palpitations
- – chest pain
Interaction with other medicinal products and other forms of interaction
The indirect sympathomimetic action of amfepramone may be increased dangerously when co-administration of adrenergic amines, antidepressants, amantadine and monoamine oxidase inhibitors (MAOIs). This applies to the MAOI within the first two weeks of the last administration of this medicine.
The need for antidiabetic drugs (eg insulin) may be influenced. Co-administration of anesthetics can produce arrhythmias. Amfepramone may reduce the effect of antihypertensive drugs, (-methyldopa).
The action of central stimulation and the appetite inhibiting effect are totally or partially antagonized by the concomitant administration of major neuroleptics (eg phenothiazines, butyrophenones).
Reviews
There are no reviews yet.